Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Ensem Therapeutics
Atavistik Bio, Inc
QuantumLeap Healthcare Collaborative
Eisai Inc.
G. d'Annunzio University
Institut du Cancer de Montpellier - Val d'Aurelle
National Institutes of Health Clinical Center (CC)
Clinica Universidad de Navarra, Universidad de Navarra
NeoImmuneTech
Alterome Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Duke University
Baptist Health South Florida
UMC Utrecht
George Washington University
Psyence Australia Pty Ltd
Eli Lilly and Company
ViroMissile, Inc.
Replimune Inc.
Hospices Civils de Lyon
Institut Curie
Duke University
University of Florida
University of Missouri-Columbia
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
Deraya University
Centre Leon Berard